These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 3285909)

  • 41. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.
    Badar T; Patel KP; Thompson PA; DiNardo C; Takahashi K; Cabrero M; Borthakur G; Cortes J; Konopleva M; Kadia T; Bohannan Z; Pierce S; Jabbour EJ; Ravandi F; Daver N; Luthra R; Kantarjian H; Garcia-Manero G
    Leuk Res; 2015 Dec; 39(12):1367-74. PubMed ID: 26547258
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study.
    Ravoet C; Mineur P; Robin V; Debusscher L; Bosly A; André M; El Housni H; Soree A; Bron D; Martiat P
    Ann Hematol; 2008 Nov; 87(11):881-5. PubMed ID: 18641985
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome.
    Shih LY; Lin TL; Wang PN; Wu JH; Dunn P; Kuo MC; Huang CF
    Cancer; 2004 Sep; 101(5):989-98. PubMed ID: 15329908
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mutations of the RAS genes in childhood acute myeloid leukemia, myelodysplastic syndrome and juvenile chronic myelocytic leukemia.
    Sheng XM; Kawamura M; Ohnishi H; Ida K; Hanada R; Kojima S; Kobayashi M; Bessho F; Yanagisawa M; Hayashi Y
    Leuk Res; 1997 Aug; 21(8):697-701. PubMed ID: 9379676
    [TBL] [Abstract][Full Text] [Related]  

  • 45. RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia.
    Hirsch-Ginsberg C; LeMaistre AC; Kantarjian H; Talpaz M; Cork A; Freireich EJ; Trujillo JM; Lee MS; Stass SA
    Blood; 1990 Sep; 76(6):1214-9. PubMed ID: 2205309
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Analysis of immunohistochemical results of the ras oncogene product p21 in myelodysplastic syndromes.
    Kalmantis T; Kalmanti M; Vassilaki M; Spandidos DA
    Anticancer Res; 1993; 13(4):1103-6. PubMed ID: 8352532
    [TBL] [Abstract][Full Text] [Related]  

  • 47. p53 mutation in the myelodysplastic syndromes.
    Adamson DJ; Dawson AA; Bennett B; King DJ; Haites NE
    Br J Haematol; 1995 Jan; 89(1):61-6. PubMed ID: 7833278
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Transforming genes and chromosome aberrations in therapy-related leukemia and myelodysplastic syndrome.
    Inokuchi K; Amuro N; Futaki M; Dan K; Shinohara T; Kuriya S; Okazaki T; Nomura T
    Ann Hematol; 1991 Jun; 62(6):211-6. PubMed ID: 1854883
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Longitudinal analysis of point mutations of the N-ras proto-oncogene in patients with myelodysplasia using archived blood smears.
    van Kamp H; de Pijper C; Verlaan-de Vries M; Bos JL; Leeksma CH; Kerkhofs H; Willemze R; Fibbe WE; Landegent JE
    Blood; 1992 Mar; 79(5):1266-70. PubMed ID: 1536950
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mechanisms of ras mutation in myelodysplastic syndrome.
    Yunis JJ; Boot AJ; Mayer MG; Bos JL
    Oncogene; 1989 May; 4(5):609-14. PubMed ID: 2657575
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia.
    Harada H; Harada Y; Niimi H; Kyo T; Kimura A; Inaba T
    Blood; 2004 Mar; 103(6):2316-24. PubMed ID: 14615365
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
    Schmitt-Graeff A; Mattern D; Köhler H; Hezel J; Lübbert M
    Pathologe; 2000 Jan; 21(1):1-15. PubMed ID: 10663664
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evi-1 and MDS1-Evi-1 genes in pathogenesis of myelodysplastic syndromes and post-MDS acute myeloid leukemia.
    Xu K; Wang L; Hao Y; Shao Z; Meng Q; Li K; Chao H; Tang K; Wang L
    Chin Med J (Engl); 1999 Dec; 112(12):1112-8. PubMed ID: 11721451
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Retrospective analysis of ras gene activation in myeloid leukemic cells.
    Lübbert M; Jonas D; Miller CW; Herrmann F; Mertelsmann R; McCormick F; Koeffler HP
    Oncogene; 1990 Apr; 5(4):583-7. PubMed ID: 2183160
    [TBL] [Abstract][Full Text] [Related]  

  • 55. BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia.
    Omidvar N; Kogan S; Beurlet S; le Pogam C; Janin A; West R; Noguera ME; Reboul M; Soulie A; Leboeuf C; Setterblad N; Felsher D; Lagasse E; Mohamedali A; Thomas NS; Fenaux P; Fontenay M; Pla M; Mufti GJ; Weissman I; Chomienne C; Padua RA
    Cancer Res; 2007 Dec; 67(24):11657-67. PubMed ID: 18089795
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Activation of ras oncogene in myelodysplastic syndrome and acute myelogenous leukemia].
    Hirai H; Hirano N; Yazaki Y
    Gan To Kagaku Ryoho; 1991 Jun; 18(7):1090-7. PubMed ID: 2053767
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.
    Kiyoi H; Naoe T; Nakano Y; Yokota S; Minami S; Miyawaki S; Asou N; Kuriyama K; Jinnai I; Shimazaki C; Akiyama H; Saito K; Oh H; Motoji T; Omoto E; Saito H; Ohno R; Ueda R
    Blood; 1999 May; 93(9):3074-80. PubMed ID: 10216104
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genomic landscape of CD34+ hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers.
    Xu L; Gu ZH; Li Y; Zhang JL; Chang CK; Pan CM; Shi JY; Shen Y; Chen B; Wang YY; Jiang L; Lu J; Xu X; Tan JL; Chen Y; Wang SY; Li X; Chen Z; Chen SJ
    Proc Natl Acad Sci U S A; 2014 Jun; 111(23):8589-94. PubMed ID: 24850867
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia.
    Tobal K; Pagliuca A; Bhatt B; Bailey N; Layton DM; Mufti GJ
    Leukemia; 1990 Jul; 4(7):486-9. PubMed ID: 2142747
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Alteration of methylation status of fragile histidine triad gene promoter in patients with myelodysplastic syndrome].
    Yao DM; Qian J; Xu WR; Lin J; Jiang YW; Fei X; Han LX; Wang Y; Cen JN; Chen ZX
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Feb; 25(1):36-9. PubMed ID: 18247301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.